The Blueberry Therapeutics project team along with CEO John Ridden, and their partner Iqvia Biotech, held an Investigator meeting in Vienna, Austria on November 8th 2019. The meeting was attended by over 50 site staff from both private and hospital based dermatology clinics across Poland, Czech Republic and Germany, and was the first opportunity for the Principal investigators to meet face-to-face with Blueberry Therapeutics. The Investigator meeting is a major step in kicking off the Phase II study in Onychomycosis and the feedback from the event was hugely positive, with real enthusiasm for the study and future potential. BB2603, which is a nanoformulation of Terbinafine, will be evaluated in a Phase II clinical trial focusing on efficacy and safety.
